Your Article Summary
See Latest ArticlesPhase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Annals of Oncology, 06/26/09
Campo JMD et al. - Both every-3-weeks trabectedin regimes, 1.5 mg/m2 24 h and 1.3 mg/m2 3 h, were active and reasonably well tolerated in AOC platinum-sensitive patients. Trabectedin every-3-weeks has promising activity and deserves to be further evaluated in relapsed AOC.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Ovarian cancer screening and early detection
Women's Health, 11/03/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Bevacizumab in the treatment of breast cancer
Cancer Treatment Reviews, 11/30/09